Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Savoldo

Showing results (31-40 of 155) with videos related to

Pageof 16
Sort By:
Nature Cancer|July 18, 2025
The landscape of CAR-engineered innate immune cells for cancer immunotherapyOurania Tsahouridis, Max Xu, Feifei Song, et al.
Blood|June 19, 2002
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cellsGianpietro Dotti, Barbara Savoldo, Patricia Yotnda, et al.
Blood|May 27, 2004
Targeted delivery of adenoviral vectors by cytotoxic T cellsPatricia Yotnda, Barbara Savoldo, Nicolas Charlet-Berguerand, et al.
Acta Haematologica|October 30, 2003
Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative diseaseCatherine M Bollard, Barbara Savoldo, Cliona M Rooney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15Yuhui Chen, Chuang Sun, Elisa Landoni, et al.
British Journal of Haematology|August 16, 2002
Immunotherapy for post-transplant lymphoproliferative diseaseKarin C M Straathof, Barbara Savoldo, Helen E Heslop, et al.
Frontiers in Immunology|January 30, 2025
Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral contextValentine Wang, Barbara Savoldo, José-Arthur Guimaraes, et al.
Virology|July 9, 2009
Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assayJunji Sashihara, Peter D Burbelo, Barbara Savoldo, et al.
Cancer Immunology, Immunotherapy : CII|September 20, 2011
Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigensBianca Altvater, Sibylle Pscherer, Silke Landmeier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2021
CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B CellsRaghuveer Ranganathan, Peishun Shou, Sarah Ahn, et al.
Pageof 16

Showing results (31-40 of 155) with videos related to

Sort By:
Pageof 16
Nature Cancer|July 18, 2025
The landscape of CAR-engineered innate immune cells for cancer immunotherapyOurania Tsahouridis, Max Xu, Feifei Song, et al.
Blood|June 19, 2002
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cellsGianpietro Dotti, Barbara Savoldo, Patricia Yotnda, et al.
Blood|May 27, 2004
Targeted delivery of adenoviral vectors by cytotoxic T cellsPatricia Yotnda, Barbara Savoldo, Nicolas Charlet-Berguerand, et al.
Acta Haematologica|October 30, 2003
Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative diseaseCatherine M Bollard, Barbara Savoldo, Cliona M Rooney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15Yuhui Chen, Chuang Sun, Elisa Landoni, et al.
British Journal of Haematology|August 16, 2002
Immunotherapy for post-transplant lymphoproliferative diseaseKarin C M Straathof, Barbara Savoldo, Helen E Heslop, et al.
Frontiers in Immunology|January 30, 2025
Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral contextValentine Wang, Barbara Savoldo, José-Arthur Guimaraes, et al.
Virology|July 9, 2009
Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assayJunji Sashihara, Peter D Burbelo, Barbara Savoldo, et al.
Cancer Immunology, Immunotherapy : CII|September 20, 2011
Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigensBianca Altvater, Sibylle Pscherer, Silke Landmeier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2021
CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B CellsRaghuveer Ranganathan, Peishun Shou, Sarah Ahn, et al.
Pageof 16